ArticleFrontiers in medicine2025
Association between eosinophil count and prognosis in chronic obstructive pulmonary disease patients.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Real-World Outcomes across Baseline Risk Profiles in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate in Spain: Insights from the ORESTES Study.Pulmonary therapy · 2026Article
- Persistently low blood eosinophils identify a high-risk phenotype in COPD.BMC pulmonary medicine · 2026Article
- Clinical Disease Burden in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation in Japan: A Retrospective Database Analysis (EUROS Study).International journal of chronic obstructive pulmonary disease · 2026Article
- Systemic inflammation, microbiology, and clinical outcomes in eosinophilic and non-eosinophilic acute exacerbations of chronic obstructive pulmonary disease.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The association between blood eosinophil levels and the risk of increased exacerbations, acute respiratory failure (ARF) and mortality in chronic obstructive pulmonary diseases (COPD) remains controversial. This association may predict future exacerbations and clinical outcomes among patients with COPD. This study aimed to clarify the relationship between eosinophil count and risk of acute exacerbation, ARF and mortality s in patients with COPD. Methods: The data for this retrospective cohort study were collected from TriNetX, a global multicentre research database. Using the Global Collaborative Research Networks, patients aged > 40 years with a diagnosis of COPD were examined for the association between blood eosinophil counts and the risk of acute exacerbation during a 3-year follow-up period. Cox proportional hazard models and Kaplan-Meier analysis were used to assess the risk of acute exacerbation between the non-eosinophilic (blood eosinophil counts <300 cells/μL) and eosinophilic groups (≥300 cells/μL) after propensity score matching. Other outcomes including survival and ARF, were also examined. Results: The non-eosinophilic group had a 1.27-fold lower risk of acute exacerbations of COPD (hazard ratio [HR], 0.790; 95% confidence interval [95% CI], 0.74-0.85; Conclusion: Increased eosinophil count may be linked to an elevated risk of exacerbation, respiratory failure, and mortality in COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.